Tag: Vaccines
Physician’s Briefing Weekly Coronavirus Roundup
Adverse Events Rare After BNT162b2 Vaccine in 5- to 11-Year-Olds
Data show 4,249 reports of adverse events after about 8.7 million doses of vaccine were administered; 97.6 percent not serious
BNT162b2 Vaccine Effectiveness 92 Percent for Teens Ages 12 to 17
Estimated vaccine effectiveness of full Pfizer-BioNTech vaccination 92 percent for preventing SARS-CoV-2 infection
FDA May Allow Pfizer Boosters for 12- to 15-Year-Olds by Monday
Agency also expected to reduce the amount of time adolescents and adults must wait between their second dose of vaccine and booster
No Effect on Ovarian Reserve Seen After mRNA COVID-19 Vaccination
Mean levels of anti-Müllerian hormone unchanged from baseline to three months after vaccination among reproductive-aged women
Vaccinated Kidney Transplant Recipients Vulnerable to SARS-CoV-2 Variants
After two-dose vaccination, only 64 and 67 percent of kidney transplant recipients showed neutralization against B.1.351 (β) and B.1.617.2 (δ)
Breakthrough COVID-19 Infection Risk Higher With Immune Dysfunction
Risk for breakthrough infection higher for those with immunocompromising conditions, such as HIV, rheumatoid arthritis, solid organ transplant
Cancer Patients With Breakthrough COVID-19 Remain at Risk for Severe Outcomes
No significant difference observed in 30-day mortality for fully vaccinated versus unvaccinated cancer patients with COVID-19
NVX-CoV2373 Vaccine Protects Against COVID-19
Study conducted in the U.S. and Mexico shows vaccine 90 percent effective overall, 100 percent effective against moderate-to-severe disease
mRNA COVID-19 Vaccine Less Protective in Elderly With Comorbidity
At ≥7 days after second dose, effectiveness of mRNA COVID-19 vaccine was 69 percent against infection, 86 percent against related death
